$599

AZ, AbbVie, Regeneron, Ionis, and GSK Q1 ’26 Earnings; Zealand and Roche to Advance Petrelintide to Ph3

A series of cardiometabolic-related news items has been observed from AstraZeneca, AbbVie, Regeneron, Ionis, GSK, and Zealand Pharma/Roche. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here